Neotropix

About:

Neotropix, Inc., a biotechnology company, develops and commercializes systemically deliverable oncolytic viruses for the treatment of

Website: http://neotropix.com

Top Investors: Quaker BioVentures, The Aurora Funds, VIMAC Milestone Medical Fund

Description:

Neotropix, Inc., a biotechnology company, develops and commercializes systemically deliverable oncolytic viruses for the treatment of neuroendocrine cancers. It develops NTX010, a naturally-occurring virus that attacks and kills neuroendocrine cancers, such as small cell lung cancer, small cell carcinomas originating in other organs, carcinoid, neuroblastoma, and certain other neuroendocrine cancers. The company was founded in 2003 and is headquartered in Malvern, Pennsylvania.

Total Funding Amount:

$11.4M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Malvern, Pennsylvania, United States

Founded Date:

2003-01-01

Contact Email:

info(AT)neotropix.com

Founders:

Paul Hallenbeck

Number of Employees:

1-10

Last Funding Date:

2009-05-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai